ID   NIKS
AC   CVCL_A1LW
SY   BC1-Ep/SL; BC-1-Ep/SL; Normal Immortal KeratinocyteS
DR   GEO; GSM2197772
DR   GEO; GSM2197773
DR   GEO; GSM2197774
DR   GEO; GSM3763043
DR   Wikidata; Q102114626
RX   Patent=US6884595;
RX   PubMed=10502513;
RX   PubMed=10692102;
RX   PubMed=20688150;
RX   PubMed=23899513;
RX   PubMed=24527287;
RX   PubMed=28623356;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12191.
CC   Biotechnology: Can be used to construct a living bioengineered skin substitute (StrataGraft) intended to provide immediate wound coverage and promote wound healaling through sustained expression by living cells of wound healing factors (PubMed=24527287).
CC   Biotechnology: Can be used to construct a human skin model (Stratatest) that can be used to assess tissue damage caused by chemical or physical agents and for the identification and characterization of agents formulated to mitigate this damage (PubMed=20688150).
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: STR profile from personal communication of Lee D.
CC   Derived from site: In situ; Foreskin, skin, epidermis; UBERON=UBERON_0001471+UBERON_0001003.
CC   Cell type: Keratinocyte; CL=CL_0000312.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 10,13
ST   D16S539: 11,13
ST   D18S51: 14,17
ST   D21S11: 31,31.2
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 11,13
ST   FGA: 20,24
ST   Penta D: 12,17
ST   Penta E: 7,17
ST   TH01: 9,10
ST   TPOX: 8
ST   vWA: 14,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   <1M
CA   Spontaneously immortalized cell line
DT   Created: 29-10-20; Last updated: 29-06-23; Version: 6
//
RX   Patent=US6884595;
RA   Allen-Hoffmann B.L., Schlosser S.J.;
RT   "Immortalized human keratinocyte cell line.";
RL   Patent number US6884595, 26-Apr-2005.
//
RX   PubMed=10502513; DOI=10.1006/viro.1999.9868;
RA   Flores E.R., Allen-Hoffmann B.L., Lee D., Sattler C.A., Lambert P.F.;
RT   "Establishment of the human papillomavirus type 16 (HPV-16) life cycle
RT   in an immortalized human foreskin keratinocyte cell line.";
RL   Virology 262:344-354(1999).
//
RX   PubMed=10692102; DOI=10.1046/j.1523-1747.2000.00869.x;
RA   Allen-Hoffmann B.L., Schlosser S.J., Ivarie C.A.R., Sattler C.A.,
RA   Meisner L.F., O'Connor S.L.;
RT   "Normal growth and differentiation in a spontaneously immortalized
RT   near-diploid human keratinocyte cell line, NIKS.";
RL   J. Invest. Dermatol. 114:444-455(2000).
//
RX   PubMed=20688150; DOI=10.1016/j.tiv.2010.07.027;
RA   Rasmussen C.A., Gratz K., Liebel F., Southall M., Garay M.,
RA   Bhattacharyya S., Simon N., Vander Zanden M., Van Winkle K.,
RA   Pirnstill J., Pirnstill S., Comer A., Allen-Hoffmann B.L.;
RT   "The StrataTest(R) human skin model, a consistent in vitro alternative
RT   for toxicological testing.";
RL   Toxicol. In Vitro 24:2021-2029(2010).
//
RX   PubMed=23899513; DOI=10.1016/j.jss.2013.06.046;
RA   Roy M., King T.W.;
RT   "Epidermal growth factor regulates NIKS keratinocyte proliferation
RT   through Notch signaling.";
RL   J. Surg. Res. 185:6-11(2013).
//
RX   PubMed=24527287; DOI=10.1089/wound.2011.0343;
RA   Schurr M.J., Foster K.N., Lokuta M.A., Rasmussen C.A.,
RA   Thomas-Virnig C.L., Faucher L.D., Caruso D.M., Allen-Hoffmann B.L.;
RT   "Clinical evaluation of NIKS-based bioengineered skin substitute
RT   tissue in complex skin defects: phase I/IIa clinical trial results.";
RL   Adv. Wound Care (New Rochelle) 1:95-103(2012).
//
RX   PubMed=28623356; DOI=10.1038/s41598-017-03295-7;
RA   Cicchini L., Blumhagen R.Z., Westrich J.A., Myers M.E., Warren C.J.,
RA   Siska C., Raben D., Kechris K.J., Pyeon D.;
RT   "High-risk human papillomavirus E7 alters host DNA methylome and
RT   represses HLA-E expression in human keratinocytes.";
RL   Sci. Rep. 7:3633-3633(2017).
//